1 in 6 NSCLC Survivors Will Face Another Lung Nodule. Here Is the Framework.

A five-step clinical framework for evaluating post-treatment pulmonary nodules in NSCLC survivors, where one in six five-year survivors develops a second primary.

Oatmeal Health is Pre-FDA 510(k), expected 2027

The scan comes back with a new 8mm solid nodule in the contralateral lobe. The patient finished lobectomy for stage II NSCLC fourteen months ago. The margins were clean. The adjuvant chemo is done. And now this.

Is it metastatic disease? A second primary? A granuloma? The imaging alone will not tell you. And the decision you make in the next thirty days will determine whether this patient gets curative-intent surgery, systemic therapy, or active surveillance.

This is the most common hard call in thoracic oncology, and it is getting more common every year. As more lung cancer patients reach the two-year and five-year marks, more are walking into follow-up appointments with new nodules. The clinical frameworks for handling them have not kept pace.